Yochai Adir has received personal fees for lecturing and/or consulting from Actelion, Boehringer Ingelheim, Teva, Bayer, GlaxoSmithKline, Roche, Novartis, AstraZeneca, Kamada and UT Pharmaceuticals, and research grants from Actelion, Bayer, Boehringer Ingelheim and GlaxoSmithKline.
Marisa Bonsignore has received grants/research support from Vivisol Italia, and honoraria or consultation fees from Bioprojet and Jazz.
Agnes Boots has nothing to disclose.
James Chalmers has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Novartis and Insmed; and received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis and Zambon.
Rachel Chambers declares receiving collaborative research funding from GlaxoSmithKline and Chiesi Farmaceutici.
Cynthia Chee has nothing to disclose.
Vincent Cottin reports grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche / Promedior, personal fees from Celgene / BMS, personal fees from Galapagos, personal fees from Galecto, personal fees from Shionogi, personal fees from Fibrogen, personal fees from RedX, personal fees from PureTech.
Bruno Crestani has received personal fees and non-financial support from Apellis, AstraZeneca, Novartis and Sanofi; grants, personal fees and non-financial support from BMS, Boehringer Ingelheim and Roche .
Sara de Matteis has nothing to disclose.
Nicolle Domnik has nothing to disclose.
Peter Dorfmüller reports consulting fees from TRiCares and Sofinnovapartners, and payment for speaking at conferences from Actelion and MSD.
Refika Ersu has nothing to disclose.
Santiago Giavedoni has nothing to disclose.
Catherine M. Greene has received research grants from Vertex, NIH and Alpha-1 Foundation.
Sergio Harari reports personal fees from Roche, grants and personal fees from AstraZeneca and Boehringer Ingelheim (in addition to being investigator in trials involving these companies, relationships include lectures and membership of scientific advisory boards and grant for research).
Georgia Hardavella has nothing to disclose.
Anne Holland reports non-financial support from BOC Australia and Air Liquide Healthcare.
Marc Humbert reports personal fees from Actelion Pharmaceuticals Ltd/Johnson & Johnson, Arena Pharmaceuticals Ltd, Pfizer and United Therapeutics, and grants and personal fees from Bayer/Merck and GlaxoSmithKline. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. Outside pulmonary vascular medicine, M. Humbert has a research interest in severe asthma and reports personal fees from AstraZeneca, Novartis, Roche/Genentech, Sanofi/Regeneron and Teva. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
Fanny Wai San Ko is conducting research on asthma with funding from Hong Kong Thoracic Society (which is supported by AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and Novartis). She is a Science Committee member of Global Initiative of Asthma.
Sandhya Khurana has received research funding (to the institution) in the past from GSK and Sanofi. No current industry funded research. No consultant, advisory board or speaker arrangements. She has research funding from American Lung Association, is on the Board of Regents for CHEST and receives royalties from Springer Nature for a textbook on asthma that she co-edited.
Kyung Soo Lee has nothing to disclose.
Y. C. Gary Lee is an honorary advisor of Lung Therapeutic Inc. Rocket Medical (UK) has provided pleural drainage kits without charge for participants of clinical trials led by Prof. Lee.
Antonella LoMauro has nothing to disclose.
Toby Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speakers fees from Apellis, AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB.
Catherine McDougall has nothing to disclose.
Marc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Spin Therapeutics, ONO Pharma, pH Pharma, Palobiofarma SL, Takeda, Novartis, Sanofi and Grifols and research grants from Grifols.
Stefano Nava is a medical advisor for Breas Medical, is on an Advisory Board for Philips and has received a research grant from Fisher & Paykel.
Renata Riha has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from JAZZ pharmaceuticals (one-off payment in 2021); has participated in a Data Safety Monitoring Board or Advisory Board for JAZZ Pharmaceuticals (completed 2020); and is co-director of Sleep Consultancy Ltd. (ongoing, payments to business).
Nicolas Roche reports grants and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Pfizer, and personal fees from Teva, AstraZeneca, Chiesi, Sanofi, and Zambon.
Dorota Sands has received advisor/speaker fees from Vertex Pharmaceuticals, Roche, Chiesi Group , Pfizer and Physio-Assist.
Laurent Savale reports grants, personal fees and non-financial support from Actelion, MSD, GlaxoSmithKline, and Bayer.
Dave Singh has received personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Synairgen, Teva, Theravance and Verona.
Giovanni Sotgiu has nothing to disclose.
Mirjam Stahl has acted as a PI, Deputy, Sub-PI in various studies, primarily on CFTR modulators in people with CF (payment to institution); was central overreader for MBW data in study VX16-809-121 for Vertex Pharmaceuticals (payment to institution). She has received funding from: German CF Foundation (Mukoviszidose e.V.) (Young Scientist sponsorship); German Federal Ministry of Education and Research (BMBF) – Junior research group “Early CF Lung Disease” at the TLRC (German Center for Lung Research, DZL); Berlin Institute of Health (BIH) (Advanced clinician scientist fellowship); and German Research Foundation (DFG) (Heisenberg professorship).
Charlotte Summers declares her laboratory has received funding from GlaxoSmithKline, Wellcome Trust, Medical Research Council, MedImmune, British Heart Foundation, and the National Institute for Health Research (NIHR) for work performed there. She is Chief Scientific Officer of Exvastat Limited, a university spinout company seeking to repurpose imatinib for ARDS.
Antoni Torres is a consultant for Pfizer, Poliphor, MSD, Jansen OM Pharma.
Donald S. Urquhart has nothing to disclose.
Omar S. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline; personal fees from Napp, Mundipharma, Sandoz, Takeda, Cipla, Covis, Novartis, Mereo Biopharma, Orion, Menarini, UCB, Trudell Medical, Deva, Kamada and Kyorin; and grants from Edmond Pharma.
Geert M. Verleden has received grants or contracts from the Broere foundation (for transplant research); payment or honoraria for lectures from GSK; and payment for participation on a Data Safety Monitoring Board or Advisory Board from Zambon.
Tobias Welte has received grants from: DFG, BMBF, EU, WHO; fees for lectures from: AstraZeneca, Bayer, Biontech, Boehringer, Berlin Chemie GSK, MSD, Novartis, Pfizer, Roche, Sanofi Aventis; and served on Advisory Boards for: AstraZeneca, Bayer, Boehringer, GSK, Novartis, Pfizer, Roche, Sanofi Aventis.
This page was last edited on 05 April 2022